June 10 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O:
MONTE ROSA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR MRT-8102, A NEK7-DIRECTED MOLECULAR GLUE DEGRADER FOR THE TREATMENT OF MULTIPLE INFLAMMATORY DISEASES
MONTE ROSA THERAPEUTICS INC - TO INITIATE PHASE 1 STUDY OF MRT-8102
MONTE ROSA THERAPEUTICS INC - PHASE 1 RESULTS FOR MRT-8102 EXPECTED IN H1 2026
Source text: ID:nGNX7Nxxtr
Further company coverage: GLUE.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.